Status:
COMPLETED
Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST
Lead Sponsor:
Radboud University Medical Center
Conditions:
Renal Cell Cancer
Colorectal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to assess the influence of Sunitinib and Sorafenib on fatigue, quality of life and depression in patients with metastatic renal cell or colorectal cancer or GIST. In order...
Detailed Description
When cure is not longer possible, cancer patients enter the palliative phase. For many types of cancer several treatment options are available. The goal of this treatment is to prolong survival, but m...
Eligibility Criteria
Inclusion
- patients with metastatic renal cell or GIST for whom treatment with Sunitinib or Sorafenib is planned
- Karnofsky score \> 70%
- age \> 18 year
- written informed consent for questionnaires
Exclusion
- contra-indications for treatment with Sunitinib or Sorafenib
- patients who do not speak or write the Dutch language adequately
- previous systemic treatment within the last 7 days before start with the study, with Sunitinib, Sorafenib or Bevacizumab
Key Trial Info
Start Date :
May 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00979329
Start Date
May 1 2008
End Date
December 1 2015
Last Update
November 28 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center Nijmegen st Radboud
Nijmegen, Netherlands, 6525 GH